SCHEMBL6009842

SCHEMBL6009842

O=C(O)[C@H](CS)NOCC(O)CO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
PTGS2 P35354 1/20 0.40
THPO P40225 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ACE P12821 1/20 0.37
LMNA P02545 2/20 0.37
FOLH1 Q04609 1/20 0.35
TGFBR1 P36897 3/20 0.33
MME P08473 1/20 0.32
OR51E2 Q9H255 1/20 0.31
DUSP3 P51452 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
FNTA P49354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6009834 0.87 TGFBR1 (0.40) KDM4ELMNATGFBR1MMEOR51E2
SCHEMBL6009597 0.81 ITGB1 (0.33) TGFBR1OR51E2
SCHEMBL6010454 0.79 FOLH1 (0.46) FOLH1
SCHEMBL27259500 0.79 TGFBR1 (0.37) KDM4EMAPTTGFBR1MEN1KMT2A
SCHEMBL6010366 0.79 ALDH1A1 (0.44) MAPTLMNAFOLH1MMEMEN1
SCHEMBL6009547 0.78 FOLH1 (0.44) FOLH1
SCHEMBL6010380 0.77 FOLH1 (0.39) KDM4ELMNAFOLH1TGFBR1DUSP3
SCHEMBL28491840 0.77 KMT2A (0.38) KDM4EALOX15BLMLMNAFOLH1
SCHEMBL6010244 0.76 MAPK1 (0.41) KDM4ELMNAFNTAFNTB
SCHEMBL6009533 0.76 FOLH1 (0.44) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060018864-A1 Cosmetic preparation containing glycerylamino acid derivative SEIWA KASEI COMPANY, LIMITED (JP) 2006-01-26 US disclosed
EP-1584320-A1 COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE Seiwa Kasei Company, Limited (JP) 2005-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060018864-A1 Cosmetic preparation containing glycerylamino acid derivative GLA, GPKOW, CUTA KDM4E 3805/4885MAPT 1841/4885THRB 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.